Catalysis Foundation for Health Taps BioFortis Labmatrix for Tuberculosis Biomarker Study | GenomeWeb

This week, BioFortis said that the Catalysis Foundation for Health has selected its Labmatrix database software system to manage an international tuberculosis diagnostic biomarker study funded by the Bill and Melinda Gates Foundation.

Specifically, CFH researchers and their collaborators will use the platform to collect and manage patient specimen data and clinical information, track shipment status, analyze data from thousands of patient biospecimens, and view real-time study results from pre-built or ad hoc data queries.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.